Skip to main content

Year: 2020

Tryg betaler udbytte på 5,25 DKK per aktie for 1.-3. kvartal 2020

Den 27. marts meddelte Tryg at man overgik til helårsudbytte for 2020, som følge af udbruddet af COVID-19, der var kendetegnet ved ekstreme rystelser i kapitalmarkederne og øget regulatorisk pres på tværs af Europa. Trygs forretningsmodel har vist sig at være meget modstandsdygtig på trods af udfordrende tider, og selskabets balanceopgørelse og solvensposition har været meget solid igennem hele perioden.   Trygs bestyrelse har i dag godkendt et ordinært udbytte på 5,25 DKK per aktie (cirka 1,6 mia. DKK). Udbetaling af udbytte for 1.-3. kvartal 2020 forventes udbetalt 12. november 2020, og handles eksklusive udbytte 10. november 2020.Udbyttebetalingen er drevet af de overordnede resultater, og en udbyttepolitik om at udbetale et nominelt, stabilt og stigende udbytte. Trygs udbyttebetaling hjælper til TryghedsGruppens medlemsbonus i 2021....

Continue reading

Galantas Increases Gold Concentrate Processing

TORONTO, Nov. 09, 2020 (GLOBE NEWSWIRE) — Galantas Gold Corporation (“Galantas” or “the company”) is pleased to announce an increase in gold concentrate processing has been achieved at the Galantas Gold Mine, Omagh, Northern Ireland.Three shift processing commenced on 26th October 2020. The addition of a third shift has increased milling from 84 hours to 120 hours per week. Additional training and labour re-organisation has enabled the change to be made, without additional hiring, by redeployment within the business. An increase in gold concentrate output of up to 43% is anticipated, due to the increase in weekly milling hours.Qualified PersonThis release has been prepared by Roland Phelps (President & CEO), qualified person under the meaning of NI. 43-101 and is based upon information prepared under his direction.NOTE REGARDING...

Continue reading

Verona Pharma Announces November 2020 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the following virtual investor conferences in November 2020:Stifel 2020 Virtual Healthcare ConferenceDate: Monday, November 16Time: 4:00 PM ET / 9:00 PM GMTJefferies Virtual London Healthcare ConferenceDate: Tuesday, November 17Time: 10:50 AM ET / 3:50 PM GMTLive webcasts of the events will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 30 days.About Verona PharmaVerona Pharma is a clinical-stage biopharmaceutical company...

Continue reading

Communiqué – Orange Romania has signed a deal to acquire a 54% controlling stake in fixed operator Telekom Romania Communications

Press ReleaseParis, 9 November 2020Orange Romania has signed a deal to acquire a 54% controlling stake in fixed operator Telekom Romania CommunicationsTelekom Romania Communications is one of Romania’s leading fixed telecom operators currently 54% owned by OTE and 46% by the Romanian State.The transaction includes the 54% stake owned by OTE and its fixed-mobile convergent subscribers.Total Enterprise Value: €497m, based on 100% of Telekom Romania Communications and the convergent customer base. This corresponds to a total purchase price of €268m for Orange, on a debt-free, cash-free basis and subject to customary adjustments at closing of the transaction.This transaction represents a major step forward in Orange’s ambitions to become the preferred choice of customers for convergent services in the Romanian market and will increase investment...

Continue reading

Communiqué – Orange Roumanie a signé un accord pour acquérir le contrôle de 54 % au sein de l’opérateur fixe Telekom Romania Communications

Communiqué de presseParis, 9 novembre 2020Orange Roumanie a signé un accord pour acquérir le contrôle de 54 % au sein de l’opérateur fixe Telekom Romania CommunicationsTelekom Romania Communications, un des principaux opérateurs fixes de Roumanie, est actuellement détenu à 54 % par OTE et à 46 % par l’État roumainLa transaction porte sur 54 % du capital détenu par OTE et sur la base d’abonnés convergents de Telekom Romania CommunicationsValeur d’entreprise totale : 497 millions d’euros, sur une base de 100 % de la valeur de Telekom Romania Communications et de sa base d’abonnés convergents. Cela correspond à un prix d’achat total de 268 M€ pour Orange, net de dette et de trésorerie et sous réserve d’ajustements usuels à la réalisation de la transactionCette acquisition représente une avancée majeure dans la stratégie d’Orange de...

Continue reading

BBS-Bioactive Bone Substitutes Plc: The whole patent regarding the product ARTEBONE® has been accepted in the USA

BBS-Bioactive Bone Substitutes Plc’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” has now been accepted in the USA. Earlier in spring (7.4.2020) we announced the acceptance of the same patent concerning the product. Now the ARTEBONE® product and its unique component, bone protein extract, are protected by patents around all major market areas globally.CEO Ilkka Kangasniemi:”The USA is the most significant market of orthopaedic products. Thus, this news about the patent approval there both for the product and production is very remarkable for our company.”More information:Ilkka Kangasniemi, CEOtel. +358 40 7080 307e-mail: ilkka.kangasniemi@bbs-artebone.fiDistribution:Nasdaq Helsinki OyNasdaq Stockholm ABMain Mediawww.bbs-artebone.fiThis is information that BBS-Bioactive Bone Substitutes...

Continue reading

BBS-Bioactive Bone Substitutes Oyj: ARTEBONE®-tuotteen patenttihakemuksen kaikki vaatimukset on hyväksytty USA:ssa

Yhtiömme BBS-Bioactive Bone Substitutes Oyj patenttihakemuksen ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” kaikki vaatimukset on nyt hyväksytty USA:ssa. Aiemmin keväällä (7.4.2020) tiedotimme samaisen patenttihakemuksen tuotevaatimusten hyväksynnästä. Nyt yhtiön kehittämä ARTEBONE®-tuote ja sen ainutlaatuinen komponentti, poron luusta eristettävä proteiiniuute, on patenttisuojattu kaikilla merkittävillä kauppa-alueilla ympäri maailmaa.Lisätietoja:Ilkka Kangasniemi, toimitusjohtaja,puh. +358 40 7080 307,s-posti: ilkka.kangasniemi@bbs-artebone.fiJAKELU:Nasdaq Helsinki OyNasdaq Stockholm ABKeskeiset tiedotusvälineetwww.bbs-artebone.fiTämä on tieto, jonka BBS-Bioactive Bone Substitutes Oyj on velvollinen julkistamaan EU:n markkinoiden väärinkäytön asetuksen mukaisesti. Tiedot on toimitettu julkaisemista...

Continue reading

DPA Group N.V.: DPA zet ook in derde kwartaal solide prestaties neer

Hoofdpunten Q3 2020:Omzet: 31,0 miljoen euro (Q3 2019: 36,2 miljoen)Brutowinst/-marge: 10,3 miljoen euro; 33,2% (Q3 2019: 11,7 miljoen; 32,3%)Herstructureringskosten vanwege COVID-19 in Q3 2020: 0,7 miljoen euroEBITDA/-marge: 5,0 miljoen euro; 16,1% (Q3 2019: 5,5 miljoen; 15,3%)Hoofdpunten YTD 2020:Omzet: 102,4 miljoen euro (2019: 111,5 miljoen)Brutowinst/-marge: 30,6 miljoen euro; 29,9% (2019: 34,6 miljoen; 31,0%)EBITDA/-marge: 13,6 miljoen euro; 13,3% (2019: 15,1 miljoen; 13,5%)Bijzondere waardevermindering op goodwill: 7,3 miljoen euro (2019: 0,0 miljoen euro)Herstructureringskosten vanwege COVID-19: 1,8 miljoen euroEén werkdag minder dan in 2019: impact 0,5 miljoen op de omzet en 0,4 miljoen op de brutowinst en EBITDA1. Op de kwartaalcijfers is geen accountantscontrole uitgevoerd. Arnold van Mameren, CEO van DPA, over de resultaten‘Corona...

Continue reading

Oma Säästöpankki Oyj:n osavuosikatsaus 1.1.-30.9.2020: Tuloksentekokyky ennätysvauhdissa

OMA SÄÄSTÖPANKKI OYJ, PÖRSSITIEDOTE 9.11.2020 KLO 8.30, OSAVUOSIKATSAUS Q3Oma Säästöpankki Oyj:n osavuosikatsaus 1.1.-30.9.2020: Tuloksentekokyky ennätysvauhdissaTämä tiedote on tiivistelmä Oma Säästöpankki Oyj:n (OmaSp) tammi-syyskuun 2020 osavuosikatsauksesta, joka on luettavissa kokonaisuudessaan tämän pörssitiedotteen liitteenä olevasta pdf-tiedostosta ja yhtiön verkkosivuilla osoitteessa www.omasp.fiToimitusjohtaja Pasi Sydänlammi:”Liiketoimintamme kehitys on jatkunut vahvana ja vuosineljännes oli pankin historian paras. Syyskuussa annoimme positiivisen tulosvaroituksen toimintaympäristön yleisestä epävarmuudesta huolimatta. Tuloksentekokykymme on ylittänyt koronakriisiä edeltäneen edellisen huipputason ja pankin liiketoiminnan kannattavuus on parantunut jopa odotettua enemmän. Pankkitoiminnan tehokkuutta kuvaavan kulu-tuottosuhteen...

Continue reading

Oma Savings Bank Plc’s Interim Report 1.1.-30.9.2020: Profitability grows at record speed

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 9 NOVEMBER 2020 AT 8.30 A.M. EET, INTERIM REPORT Q3 Savings Bank Plc’s Interim Report 1.1.-30.9.2020: Profitability grows at record speedThis release is a summary of Oma Savings Bank’s (OmaSp) January-September 2020 Interim Report, which can be read from the pdf file attached to this stock exchange release and on the company’s web pages www.omasp.fi CEO Pasi Sydänlammi:”Our business has continued strong and the quarter was the best in the bank’s history. In September, we issued a positive profit warning despite the general uncertainty in the operating environment. Our profitability has exceeded the previous peak prior to the corona crisis and the bank’s business profitability has improved even more than expected. In terms of the cost/income ratio that describes banking efficiency, we have achieved...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.